Avalo Therapeutics initiated with a Neutral at H.C. Wainwright

H.C. Wainwright analyst Edward White initiated coverage of Avalo Therapeutics (AVTX) with a Neutral rating and no price target The firm says the company’s AVTX-009 has promise to treat inflammatory diseases. The analyst waits for the initial hidradenitis suppurativa data and for the company to progress further along with the Phase 2 study.